Sanofi (SNYNF, SNY) said the company recorded a solid business performance in the second quarter, led by the strong launch of Dupixent driven by the accelerated uptake in atopic dermatitis and asthma in the U.S. The company has revised upward its guidance for full-year business EPS growth to approximately 5%.
from RTT - Earnings https://ift.tt/2yijlE3
via IFTTT
No comments:
Post a Comment